SynthesisJAMA neurology2014
Dietary ω-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis.
Synthesis in JAMA neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03659422 (Dietary Approach to Improving QoL in ALS), which is not on this map. Cited by 71 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dietary Approach to Improving QoL in ALS
Who cites it
71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Environmental risk factors, protective factors, and biomarkers for amyotrophic lateral sclerosis: an umbrella review.Frontiers in aging neuroscience · 2025Pooled it
- Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2023Pooled it
- Lipidomics study of plasma from patients suggest that ALS and PLS are part of a continuum of motor neuron disorders.Scientific reports · 2021Trial
- Unraveling the role of lipid metabolism in ALS risk: a Mendelian randomization analysis using GWAS data.Orphanet journal of rare diseases · 2026Article
- Association of dietary inflammatory index with body composition and disease progression in adults with amyotrophic lateral sclerosis: evidence from a cross-sectional study.BMC nutrition · 2026Article
- Disrupted astrocyte-neuron metabolic coupling in amyotrophic lateral sclerosis.Frontiers in cell and developmental biology · 2026Review
- Anti-Neuroinflammation Activity of Essential Oils and Fatty Acids.Food science & nutrition · 2026Review
- Analysis of factors influencing sleep disorders in patients with amyotrophic lateral sclerosis.Scientific reports · 2025Article
- The Emerging Role of the Brain-Gut Axis in Amyotrophic Lateral Sclerosis: Pathogenesis, Mechanisms, and Therapeutic Perspectives.International journal of molecular sciences · 2025Review
- Glycerophospholipids in ALS: insights into disease mechanisms and clinical implication.Molecular neurodegeneration · 2025Review
- Mediterranean dietary pattern and risk of neurodegenerative diseases in a cohort of Swedish women.NPJ Parkinson's disease · 2025Article
- Neuronal polyunsaturated fatty acids are protective in ALS/FTD.Nature neuroscience · 2025Article
- Nutritional and Microbiota-Based Approaches in Amyotrophic Lateral Sclerosis: From Prevention to Treatment.Nutrients · 2024Review
- Increased Vulnerability to Ferroptosis in FUS-ALS.Biology · 2024Article
- Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2024Review
- Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases.Signal transduction and targeted therapy · 2024Review
- Gut Symptoms, Gut Dysbiosis and Gut-Derived Toxins in ALS.International journal of molecular sciences · 2024Review
- Ketogenic effect of coconut oil in ALS patients.Frontiers in nutrition · 2024Article
- The amyotrophic lateral sclerosis exposome: recent advances and future directions.Nature reviews. Neurology · 2023Review
- Integrative proteomics highlight presynaptic alterations and c-Jun misactivation as convergent pathomechanisms in ALS.Acta neuropathologica · 2023Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
Abstract
importanceAmyotrophic lateral sclerosis (ALS) is a severe progressive disease that cannot be prevented or cured. Diet-derived long-chain polyunsaturated fatty acids (PUFAs) are incorporated in brain lipids and modulate oxidative and inflammatory processes and could thus affect ALS risk and progression.
objectiveTo examine the association between ω-6 and ω-3 PUFA consumption and ALS risk. DESIGN, SETTING, AND
participantsLongitudinal analyses based on 1,002,082 participants (479,114 women and 522,968 men) in 5 prospective cohorts: the National Institutes of Health-AARP Diet and Health Study, the Cancer Prevention Study II Nutrition Cohort, the Health Professionals Follow-up Study, the Multiethnic Cohort Study, and the Nurses' Health Study. Diet was assessed via food frequency questionnaire developed or modified for each cohort. Participants were categorized into cohort-specific quintiles of intake of energy-adjusted dietary variables. MAIN OUTCOMES AND MEASURES: Cohort-specific multivariable-adjusted risk ratios (RRs) of ALS incidence or death estimated by Cox proportional hazards regression and pooled using random-effects methods.
resultsA total of 995 ALS cases were documented during the follow-up. A greater ω-3 PUFA intake was associated with a reduced risk for ALS. The pooled, multivariable-adjusted RR for the highest to the lowest quintile was 0.66 (95% CI, 0.53-0.81; P < .001 for trend). Consumption of both α-linolenic acid (RR, 0.73; 95% CI, 0.59-0.89; P = .003 for trend) and marine ω-3 PUFAs (RR, 0.84; 95% CI, 0.65-1.08; P = .03 for trend) contributed to this inverse association. Intakes of ω-6 PUFA were not associated with ALS risk. CONCLUSIONS AND RELEVANCE: Consumption of foods high in ω-3 PUFAs may help prevent or delay the onset of ALS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.